Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Stitch Fix Helps Nasdaq Stretch Toward Records; Curis Erupts Higher

By Dan Caplinger - Dec 8, 2020 at 2:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Further gains for the top stock market came from big movers.

The stock market has seemed unstoppable lately, and the Nasdaq Composite ( ^IXIC -1.80% ) has been leading the way higher all year. The Nasdaq extended its year-to-date gains to more than 40% on Tuesday afternoon, with the index climbing about half a percent as of just before 2 p.m. EST.

The biggest stocks in the Nasdaq were fairly quiet on Tuesday, but some smaller players had some blockbuster news to announce. Stitch Fix ( SFIX -6.38% ) reported financial results that wowed shareholders who've had to be patient for a while. At the same time, upstart Curis ( CRIS -1.86% ) vaulted into the spotlight with a huge gain.

Stitching together a big bump higher

Shares of Stitch Fix soared 42% on Tuesday afternoon. The subscription-based fashion curator and apparel home-delivery specialist once again delivered great results, but for the first time in a long time, investors seemed to appreciate its performance fully.

Stitch Fix box on doorstep in front of purple door and blue wall

Image source: Stitch Fix.

The numbers spoke for themselves. Fiscal first-quarter revenue climbed 10%, with Stitch Fix adding 241,000 new clients in just the past three months to reach nearly 3.8 million subscribers. Moreover, the company was profitable, posting net income of $9.5 million and earnings of $0.09 per share.

Even more importantly, Stitch Fix reached record-high levels of success in giving people clothing they wanted to keep. First-shipment performance was the best in more than five years, and that's a particularly essential component of the service's long-term prospects, because first impressions are critical in determining whether new subscribers will stick with the company over the long run.

Investors in Stitch Fix had to wait years for it to gain momentum. With the COVID-19 pandemic continuing to drive shop-from-home interest, the new upward trend could last quite a while.

Curis starts its cancer fight strong

Gains for Curis were even more impressive, with the stock up a whopping 340%. The tiny biotech company produced encouraging study results that could point to a new treatment for a common disease.

Curis has been doing a phase 1 study of its CA-4948 protein kinase inhibitor in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. The study involved using CA-4948 as a single therapy, and preliminary data showed that all participating patients showed reductions in marrow blast, with some showing a favorable complete response with respect to marrow. The treatment showed no dose-limiting toxicity issues at this stage in the trial.

The company intends to continue the phase 1 study, with the hope of reporting more data by the second half of next year. Moreover, it's also conducting an early-stage study of the treatment in patients with non-Hodgkin lymphoma.

Investors have high hopes that Curis will join the worldwide fight against all forms of cancer successfully. If more positive results follow, then today's gains could be just the beginning for the biotech stock .

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

StitchFix Stock Quote
StitchFix
SFIX
$24.67 (-6.38%) $-1.68
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$15,498.53 (-1.80%) $-284.30
Curis, Inc. Stock Quote
Curis, Inc.
CRIS
$4.75 (-1.86%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.